CSF3 and acute myeloid leukemia: Clinical studies that examined the combination of decitabine and chemotherapeutics, such as standard DA (daunomycin and cytarabine), low-dose AA, and CAG (G-CSF and low-dose AA) suggested CR rate at 50–60% and OR rate at 60–90% in AML and MDS/AML (Li et al. 2015; Scandura et al. 2011; Song et al. 2012).